

AstraZeneca Docket No. PHIM.70293/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: **Aiyar, J., et al.**
Filed: **December 10, 1998**
Application No. **09/209,125**
For: **HUMAN BRAIN-DERIVED TISSUE-SPECIFIC
POTASSIUM CHANNEL**

Group Art Unit: 1646
Examiner: Nirmal S. Basi

Assistant Commissioner for Patents
Washington, DC 20231

RESPONSE TO OFFICE ACTION

Sir:

Applicants hereby respond to an Office Action dated June 20, 2000. This response is filed within the statutory period permitted for response and includes a petition for an extension of time to respond to the aforesaid Office Action.

PETITION

Applicants enclose form PTO/SB/22 petitioning for a three month extension of time to respond to an office action.

FEES

Applicants enclose form PTO/SB/17 requesting that all fees required by the filing of this response be charged to Deposit Account 26-0166.

AMENDMENTIn the Claims:

Please amend the Claims as follows:

- B1
1. (amended) A purified polynucleotide comprising a nucleic acid sequence [encoding the] which encodes a polypeptide [having the] comprising a sequence having at least 85% total sequence similarity to [substantially as depicted in] SEQ ID NO:3 or a biologically active fragment thereof.
- sub
c1

OFFICIAL